Structural and Dynamic Basis of TREM2--DAP12 Stabilization by Small-Molecule Agonist VG-3927
Fanyu ZhaoiD, Wei XiaiD, Xintai Zhang, Xue WuiD, Junxiao Ding, Xiangyue Li, John Z.H. ZhangiD
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is an important microglial receptor implicated in Alzheimers disease, but the structural basis of small-molecule TREM2 agonism remains poorly understood. In particular, the clinical-stage agonist VG-3927 has been reported to promote TREM2-DAP12 complex formation, suggesting a mechanism distinct from conventional recognition at the ectodomain surface. Here, we propose that VG-3927 binds within a membrane-embedded interfacial cavity formed by the transmembrane helices of TREM2, DAP12A, and DAP12B. Our simulations support a stable and reproducible cavity-bound pose that is maintained across independent trajectories and is anchored by a persistent hotspot network dominated by hydrophobic and van der Waals interactions. Rather than merely occupying a pre-existing pocket, VG-3927 reshapes the surrounding transmembrane assembly by reinforcing selected interhelical contacts, strengthening receptor-adaptor hydrogen-bond coupling, and biasing the three-helix bundle toward a more compact, more upright, and more conformationally focused state. Importantly, the ligand-bound ensemble remains within a subdomain of the apo conformational landscape, consistent with stabilization of a pre-existing but less populated signaling-relevant state. Together, these findings support a membrane-asscosiated mechanism in which VG-3927 acts as a transmembrane interfacial molecular glue, biasing the TREM2-DAP12 complex toward a more compact, ordered, and signaling-competent state. This finding can provide a structural framework for understanding small-molecule TREM2 agonism.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Aβ-Overlapping Ectodomain Binding of the Clinical-Stage TREM2 Agonist VG-3927
Sungwoo Cho, Moustafa Tarek Gabr·bioRxiv·Mar 5, 2026
- Discovery of an Achiral Small Molecule TREM2 Agonist with Im-proved Pharmacokinetic Profile and Validated Target Engagement
Shaoren Yuan, Farida El Gaamouch, … Moustafa Tarek Gabr·bioRxiv·Jun 22, 2025
- Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis
Sungwoo Cho, Baljit Kaur, … Moustafa Tarek Gabr·ChemMedChemPeer-reviewed·Jan 1, 2026
- TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional Characterization
Hossam Nada, Shaoren Yuan, … Moustafa Tarek Gabr·European Journal of Medicinal ChemistryPeer-reviewed·Nov 15, 2025
- Understanding the binding mechanisms of Alzheimer risk factor TREM2 in lipid bilayer using multi-scale molecular dynamics simulations
Zhiwen Zhong, Martin B. Ulmschneider, Christian D. Lorenz·ACS OmegaPeer-reviewed·Jun 21, 2024
- Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer's Models
Hossam Nada, Shaoren Yuan, … Moustafa Tarek Gabr·European Journal of Medicinal Chemistry ReportsPeer-reviewed·Jun 9, 2026